This article is more than 5 years old. Information may no longer be current.

Brachytherapy device in trials for AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BUFORD, Ga. — A system for ocular brachytherapy will begin human trials for the treatment of subfoveal choroidal neovascularization associated with exudative wet age-related macular degeneration, the system’s developer announced in a press release.

The Food and Drug Administration granted an investigational device exemption to Theragenics Corp. to begin its pilot study of the TheraSight Ocular Brachytherapy System, the company said. The pilot trial will assess three doses of radiation in 30 patients at up to six clinical sites, according to the company.

Theragenics is the manufacturer and marketer of the palladium-103 device TheraSeed and an iodine-125-based device, I-Seed. Both are used in the treatment of localized prostate cancer, the company said.